Cite
HARVARD Citation
Bossuyt, P. et al. (n.d.). OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. Journal of Crohn's and colitis. pp. S033-S034. [Online].